BAUSCH Company Profile
✉ Email this page to a colleague
What is the competitive landscape for BAUSCH, and what generic alternatives to BAUSCH drugs are available?
BAUSCH has one hundred and seventy-eight approved drugs.
There are one hundred and twenty-three US patents protecting BAUSCH drugs.
There are seven hundred and seventy-eight patent family members on BAUSCH drugs in fifty-two countries and two hundred and twelve supplementary protection certificates in sixteen countries.
Summary for BAUSCH
| International Patents: | 778 |
| US Patents: | 123 |
| Tradenames: | 157 |
| Ingredients: | 123 |
| NDAs: | 178 |
| Patent Litigation for BAUSCH: | See patent lawsuits for BAUSCH |
Drugs and US Patents for BAUSCH
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bausch | APLENZIN | bupropion hydrobromide | TABLET, EXTENDED RELEASE;ORAL | 022108-002 | Apr 23, 2008 | RX | Yes | No | 7,572,935 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Bausch | APLENZIN | bupropion hydrobromide | TABLET, EXTENDED RELEASE;ORAL | 022108-003 | Apr 23, 2008 | RX | Yes | Yes | 7,671,094 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Bausch | NORFLEX | orphenadrine citrate | TABLET, EXTENDED RELEASE;ORAL | 012157-001 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | |||||
| Bausch | APLENZIN | bupropion hydrobromide | TABLET, EXTENDED RELEASE;ORAL | 022108-001 | Apr 23, 2008 | RX | Yes | No | 7,662,407 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Bausch And Lomb | TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE | polymyxin b sulfate; trimethoprim sulfate | SOLUTION/DROPS;OPHTHALMIC | 064120-001 | Feb 14, 1997 | AT | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
| Bausch | SOLODYN | minocycline hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 050808-004 | Jul 23, 2009 | DISCN | Yes | No | 8,268,804 | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for BAUSCH
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Bausch | ZOVIRAX | acyclovir | OINTMENT;TOPICAL | 018604-001 | Mar 29, 1982 | 4,199,574 | ⤷ Sign Up |
| Bausch | TARGRETIN | bexarotene | GEL;TOPICAL | 021056-001 | Jun 28, 2000 | 7,655,699 | ⤷ Sign Up |
| Bausch | TIAZAC | diltiazem hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 020401-002 | Sep 11, 1995 | 6,162,463 | ⤷ Sign Up |
| Bausch And Lomb Inc | TIMOPTIC IN OCUDOSE | timolol maleate | SOLUTION/DROPS;OPHTHALMIC | 019463-001 | Nov 5, 1986 | 3,655,663 | ⤷ Sign Up |
| Bausch | CARDIZEM LA | diltiazem hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 021392-005 | Feb 6, 2003 | 7,108,866 | ⤷ Sign Up |
| Bausch | ZELAPAR | selegiline hydrochloride | TABLET, ORALLY DISINTEGRATING;ORAL | 021479-001 | Jun 14, 2006 | 5,648,093 | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for BAUSCH drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Gel | 1.2%/2.5% | ➤ Subscribe | 2012-12-20 |
| ➤ Subscribe | Extended-release Tablets | 150 mg and 300 mg | ➤ Subscribe | 2004-09-21 |
| ➤ Subscribe | Gel | 0.1% | ➤ Subscribe | 2010-07-08 |
| ➤ Subscribe | Ophthalmic Solution | 0.07% | ➤ Subscribe | 2013-07-26 |
| ➤ Subscribe | Capsules | 75 mg | ➤ Subscribe | 2011-06-06 |
| ➤ Subscribe | Vaginal Gel | 0.75% | ➤ Subscribe | 2004-09-02 |
| ➤ Subscribe | Cream | 5% | ➤ Subscribe | 2006-10-17 |
| ➤ Subscribe | Topical Solution | 10% | ➤ Subscribe | 2018-06-06 |
| ➤ Subscribe | Cream | 0.10% | ➤ Subscribe | 2008-01-31 |
| ➤ Subscribe | Extended-release Tablets | 348 mg | ➤ Subscribe | 2009-09-24 |
| ➤ Subscribe | Cream | 2.5% | ➤ Subscribe | 2014-06-17 |
| ➤ Subscribe | Extended-release Tablets | 120 mg, 180 mg, 240 mg, 300 mg and 360 mg | ➤ Subscribe | 2005-08-30 |
| ➤ Subscribe | Rectal Gel | 2.5 mg/0.5 mL, 5 mg/mL, 10 mg/2 mL, 15 mg/3 mL and 20 mg/4 mL | ➤ Subscribe | 2004-03-23 |
| ➤ Subscribe | Extended-release Tablets | 65 mg and 115 mg | ➤ Subscribe | 2009-11-19 |
| ➤ Subscribe | Rectal Gel | 5 mg/mL, 2mL pre-filled syringe | ➤ Subscribe | 2008-12-23 |
| ➤ Subscribe | Extended-release Tablet | 105 rng | ➤ Subscribe | 2010-12-28 |
| ➤ Subscribe | Gel | 1.2%/3.75% | ➤ Subscribe | 2015-09-30 |
| ➤ Subscribe | Ophthalmic Solution | 0.5% | ➤ Subscribe | 2012-10-19 |
| ➤ Subscribe | Gel | 0.04% | ➤ Subscribe | 2010-12-20 |
| ➤ Subscribe | Ophthalmic Solution | 1.5% | ➤ Subscribe | 2013-09-09 |
| ➤ Subscribe | Gel | 1.2%/0.025% | ➤ Subscribe | 2010-12-17 |
| ➤ Subscribe | Gel | 0.77% | ➤ Subscribe | 2006-05-10 |
| ➤ Subscribe | Lotion | 0.1% | ➤ Subscribe | 2016-08-31 |
| ➤ Subscribe | Extended-release Tablets | 174 mg | ➤ Subscribe | 2009-09-28 |
| ➤ Subscribe | Cream | 3.75% | ➤ Subscribe | 2012-08-08 |
| ➤ Subscribe | Extended-release Tablets | 522 mg | ➤ Subscribe | 2009-12-24 |
| ➤ Subscribe | For Inhalation Solution | 6 gm/vial | ➤ Subscribe | 2014-05-22 |
| ➤ Subscribe | Extended-release Tablets | 420 mg | ➤ Subscribe | 2005-04-25 |
| ➤ Subscribe | Rectal Gel | 5 mg/mL, 4mL pre-filled syringe | ➤ Subscribe | 2008-12-08 |
| ➤ Subscribe | Extended-release Tablet | 55 mg and 80 mg | ➤ Subscribe | 2010-12-02 |
International Patents for BAUSCH Drugs
Supplementary Protection Certificates for BAUSCH Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2666774 | CA 2020 00037 | Denmark | ⤷ Sign Up | PRODUCT NAME: RELEBACTAM, OPTIONALLY IN THE FORM OF THE MONOHYDRATE, IMIPENEM AND CILASTATIN, OPTIONALLY IN THE FORM OF THE SODIUM SALT; REG. NO/DATE: EU/1/19/1420 20200217 |
| 2826776 | 2021C/517 | Belgium | ⤷ Sign Up | PRODUCT NAME: SYMKEVI - TEZACAFTOR/IVACAFTOR; EEN COMBINATIE VAN (A) (R)-1-(2,2-DIFLUOROBENZO(D)(1,3)DIOXOL-5-YL)-N-(1-(2,3-DIHYDROXYPROPYL)-6-FLUORO-2-(1-HYDROXY-2-METHYLPROPAN-2-YL)-1H-INDOL-5-YL)CYCLOPROPANECARBOXAMIDE OF EEN VANUIT FARMACEUTISCH OOGPUNT GESCHIKT ZOUT DAARVAN EN (B) N-(5-HYDROXY-2,4-DITERT-BUTYL-PHENYL)-4-OXO-1H-QUINOLINE-3-CARBOXAMIDE OF EEN VANUIT FARMACEUTISCH OOGPUNT GESCHIKT ZOUT DAARVAN; AUTHORISATION NUMBER AND DATE: EU/1/18/1306 20181106 |
| 2822954 | SPC/GB18/031 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: BICTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR BICTEGRAVIR SODIUM.; REGISTERED: UK EU/1/18/1289/001(NI) 20180625; UK EU/1/18/1289/002(NI) 20180625; UK PLGB 11972/0008 20180625 |
| 1948158 | 93075 | Luxembourg | ⤷ Sign Up | PRODUCT NAME: SACUBITRIL ET VALSARTAN, SOUS FORME DE COMPLEXE SODIQUE SACUBITRIL VALSARTAN, C'EST-A-DIRE DE (3-((1S,3R)-1-BIPHENYL-4-YLMETHYL-3-ETHOXYCARBONYL-1-BUTYLCARBAMOYL)PROPIONATE-(S)-3'-METHYL-2-(PENTANYOL(2''-(TETRAZOL-5-YLATE)BIPHENYL-4'-YLMETHYL)AMINO)BUTYRATE) DE TRISODIUM HEMIPENTAHYDRATE; AUTHORISATION NUMBER AND DATE: EU/1/15/1058 20151123 |
| 0427680 | 12/2003 | Austria | ⤷ Sign Up | PRODUCT NAME: PIMECROLIMUS, GEGEBENENFALLS IN FORM PHARMAZEUTISCH ANNEHMBARER SALZE; NAT. REGISTRATION NO/DATE: 1-24689 20020917; FIRST REGISTRATION: DK 21034 20020315 |
| 0352076 | 1/2001 | Austria | ⤷ Sign Up | PRODUCT NAME: VERTEPORFIN; REGISTRATION NO/DATE: EU/1/00/140/001 20000727 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
